WAVEMAN · COMPANY

MEDP · Medpace Holdings, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

MEDP

Name: Medpace Holdings, Inc. (MEDP) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Medpace Holdings, Inc.

PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0001668397

CONGRESS · 1FORM 144 · 10☆ WATCH

INSIDER NET · 180D

-$104.4M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

282

13F, latest reported quarter

REVENUE GROWTH

+20.0%

XBRL, annual

NET MARGIN

17.8%

CONVERSIONS · 180D

codes C/M, not in net · $12.1M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$104.4M over 180 days

-$82.6M over 90 days · -$65.0M of it by a 10%+ holder

below 98% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

282 funds added or opened last quarter

more than 93% of Pharma & Biotech

REVENUE

+20.0% year over year

more than 69% of Pharma & Biotech

MARGIN

17.8% net margin

more than 87% of Pharma & Biotech

BUYBACKS

$294.8M repurchased, FY to 2026-06-30

more than 81% of Pharma & Biotech

SHORT

6.3% of shares outstanding short · 3.8 days to cover · settled 2026-07-31

more than 61% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$104.4M across 9 people in 180 days.

282 funds added or opened positions in the latest 13F quarter, of 700 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +25.4%

+25.4%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $104.4M sold by insiders over 180 days, 282 funds added last quarter, 1 Congress member(s) bought in 12 months, $211.7M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Medpace Holdings, Inc. insiders sold a net $104.4M of stock across 335 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Troendle August J.

President & CEO

SELL

2026-08-27

650.0

$403.2K

Troendle August J.

President & CEO

SELL

2026-08-26

4,000.0

$2.5M

Kraft Robert O.

Director

SELL

2026-08-26

3,858.0

$2.4M

Troendle August J.

President & CEO

SELL

2026-08-25

673.0

$417.5K

Troendle August J.

President & CEO

SELL

2026-08-24

1,983.0

$1.2M

335 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 330 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

2,498,248.0 sh

$1.3B

AQR CAPITAL MANAGEMENT LLC

1,278,935.0 sh

$677.3M

VANGUARD PORTFOLIO MANAGEMENT LLC

1,133,357.0 sh

$600.2M

VANGUARD CAPITAL MANAGEMENT LLC

1,026,820.0 sh

$543.8M

STATE STREET CORP

710,895.0 sh

$376.5M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Kraft Robert O.

FILED 2026-08-26

$2.4M

Brady Kevin M.

FILED 2026-08-20

$2.1M

Carley Brian T

FILED 2026-08-19

$3.0M

DAVENPORT FRED B JR

FILED 2026-08-19

$4.4M

McCarthy Cornelius P. III

FILED 2026-08-11

$690.1K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Wasatch Long/Short Alpha Fund

$1.4M POSITION · AS OF 2026-03-31

4.0%

Vulcan Value Partners Small Cap Fund

$3.4M POSITION · AS OF 2026-04-30

3.7%

Catalyst Insider Buying Fund

$571.4K POSITION · AS OF 2026-03-31

3.7%

DF DENT SMALL CAP GROWTH FUND

$5.5M POSITION · AS OF 2026-03-31

3.7%

Wasatch Small Cap Growth Fund

$43.3M POSITION · AS OF 2026-03-31

3.6%

ERSHARES GLOBAL ENTREPRENEURS

$1.4M POSITION · AS OF 2026-03-31

3.6%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · August J. Troendle

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$11.4M

$11.7M

$2.2M

+303%

-1%

2024

$8.6M

$17.7M

$4.2M

+139%

-19%

2023

$1.6M

$9.3M

$918.6K

+120%

-18%

2022

$1.9M

$12.9M

$1.0M

+53%

-23%

2021

$5.9M

$7.7M

$2.0M

+56%

-4%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.5B	$2.1B	$1.9B	$1.5B
OPERATING INCOME	$534.9M	$446.9M	$336.8M	$278.7M
NET INCOME	$451.1M	$404.4M	$282.8M	$245.4M
EPS (DILUTED)	15.28	12.63	8.88	7.28
OPERATING CASH FLOW	$713.2M	$608.8M	$433.4M	$388.1M
CASH	$497.0M	$669.4M	$245.4M	$28.3M
BUYBACKS	$917.4M	$169.9M	$144.0M	$847.8M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE